Skip to main content
Careers
Contact us
Company
About Us
Management
Board of Directors
Advisory Board
Therapeutic Focus
Neurological Disorders
Chronic Pain
Hair Loss Disorders
Science and Technology
Exicure's Approach
References and Papers
Pipeline
Pipeline
Collaboration Programs
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Form 8937
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
News
Company
About Us
Management
Board of Directors
Advisory Board
Scientific Team
Therapeutic Focus
Genetic Disorders
Oncology
Science and Technology
Pipeline
Pipeline
AST-008
XCUR-FXN
Collaboration Programs
Compassionate Use Policy
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Form 8937
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
Normal
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
12/12/2016
Exicure Enters Into a Strategic Alliance with Purdue Pharma L.P.
10/11/2016
Exicure Announces Positive Phase 1 Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
Download
PDF format download (opens in new window)
04/26/2016
Exicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis
Download
PDF format download (opens in new window)
02/12/2016
Exicure Co-Founder Awarded Prestigious Dan David Prize
Download
PDF format download (opens in new window)